Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,762 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Mazières J, et al. Among authors: peters s. J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi: 10.1200/JCO.2012.45.6095. Epub 2013 Apr 22. J Clin Oncol. 2013. PMID: 23610105
Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O. Berthod G, et al. Among authors: peters s. J Clin Oncol. 2012 Jun 10;30(17):e156-9. doi: 10.1200/JCO.2011.39.3298. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547608 No abstract available.
MET: a promising anticancer therapeutic target.
Peters S, Adjei AA. Peters S, et al. Nat Rev Clin Oncol. 2012 May 8;9(6):314-26. doi: 10.1038/nrclinonc.2012.71. Nat Rev Clin Oncol. 2012. PMID: 22566105 Review.
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Gautschi O, Dingemans AM, Crowe S, Peters S, Roder H, Grigorieva J, Roder J, Zappa F, Pless M, Brutsche M, Baty F, Bubendorf L, Hsu Schmitz SF, Na KJ, Carbone D, Stahel R, Smit E. Gautschi O, et al. Among authors: peters s. Lung Cancer. 2013 Jan;79(1):59-64. doi: 10.1016/j.lungcan.2012.10.006. Epub 2012 Nov 1. Lung Cancer. 2013. PMID: 23122759
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J. Gautschi O, et al. Among authors: peters s. Lung Cancer. 2013 Nov;82(2):365-7. doi: 10.1016/j.lungcan.2013.08.012. Epub 2013 Aug 19. Lung Cancer. 2013. PMID: 24035431
Strategies for improving outcomes in NSCLC: a look to the future.
Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA. Stahel R, et al. Among authors: peters s. Lung Cancer. 2013 Dec;82(3):375-82. doi: 10.1016/j.lungcan.2013.08.025. Epub 2013 Sep 8. Lung Cancer. 2013. PMID: 24094287 Free article. Review.
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA. Blackhall FH, et al. Among authors: peters s. J Clin Oncol. 2014 Sep 1;32(25):2780-7. doi: 10.1200/JCO.2013.54.5921. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071109
3,762 results